CLIC Detector and Physics Status

This contribution to LCWS2016 presents recent developments within the CLICdp collaboration. An updated scenario for the staged operation of CLIC has been published; the accelerator will operate at 380 GeV, 1.5 TeV and 3 TeV. The lowest energy stage is optimised for precision Higgs and top physics, while the higher energy stages offer extended Higgs and BSM physics sensitivity. The detector models CLIC_SiD and CLIC_ILD have been replaced by a single optimised detector; CLICdet. Performance studies and R&D in technologies to meet the requirements for this detector design are ongoing.Comment: Talk presented at the International Workshop on Future Linear Colliders (LCWS2016), Morioka, Japan, 5-9 December 2016. C16-12-05.

A time resolved study of injection backgrounds during the first commissioning phase of SuperKEKB

We report on measurements of beam backgrounds during the first commissioning phase of the SuperKEKB collider in 2016, performed with the plastic scintillator and silicon photomultiplier-based CLAWS detector system. The sub-nanosecond time resolution and single particle detection capability of the sensors allow bunch-by-bunch measurements, enable CLAWS to perform a novel time resolved analysis of beam backgrounds, and make the system uniquely suited for the study of injection backgrounds. We present measurements of various aspects of regular beam background and injection backgrounds which include time structure and decay behavior of injection backgrounds, hit-energy spectra and overall background rates. These measurements show that the elevated background rates following an injection generally last for several milliseconds, with the majority of the background particles typically observed within the first 500 us. The injection backgrounds exhibit pronounced patterns in time, connected to betatron and synchrotron oscillations in the accelerator rings. The frequencies of these patterns are determined from detector data.Comment: 19 pages, 12 figures, published in EPJ

Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model

Imiquimod (IMQ) is a topical agent that induces local inflammation via the Toll-like receptor 7 pathway. Recently, an IMQ-driven skin inflammation model was developed in healthy volunteers for proof-of-pharmacology trials. The aim of this study was to profile the cellular, biochemical, and clinical effects of the marketed anti-inflammatory compound prednisolone in an IMQ model. This randomized, double-blind, placebo-controlled study was conducted in 24 healthy volunteers. Oral prednisolone (0.25 mg/kg/dose) or placebo (1:1) was administered twice daily for 6 consecutive days. Two days after treatment initiation with prednisolone or placebo, 5 mg imiquimod (IMQ) once daily for two following days was applied under occlusion on the tape-stripped skin of the back for 48 h in healthy volunteers. Non-invasive (imaging and biophysical) and invasive (skin punch biopsies and blister induction) assessments were performed, as well as IMQ ex vivo stimulation of whole blood. Prednisolone reduced blood perfusion and skin erythema following 48 h of IMQ application (95% CI [−26.4%, −4.3%], p = 0.0111 and 95% CI [−7.96, −2.13], p = 0.0016). Oral prednisolone suppressed the IMQ-elevated total cell count (95% CI [−79.7%, −16.3%], p = 0.0165), NK and dendritic cells (95% CI [−68.7%, −5.2%], p = 0.0333, 95% CI [−76.9%, −13.9%], p = 0.0184), and classical monocytes (95% CI [−76.7%, −26.6%], p = 0.0043) in blister fluid. Notably, TNF, IL-6, IL-8, and Mx-A responses in blister exudate were also reduced by prednisolone compared to placebo. Oral prednisolone suppresses IMQ-induced skin inflammation, which underlines the value of this cutaneous challenge model in clinical pharmacology studies of novel anti-inflammatory compounds. In these studies, prednisolone can be used as a benchmark.</p

Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model

Imiquimod (IMQ) is a topical agent that induces local inflammation via the Toll-like receptor 7 pathway. Recently, an IMQ-driven skin inflammation model was developed in healthy volunteers for proof-of-pharmacology trials. The aim of this study was to profile the cellular, biochemical, and clinical effects of the marketed anti-inflammatory compound prednisolone in an IMQ model. This randomized, double-blind, placebo-controlled study was conducted in 24 healthy volunteers. Oral prednisolone (0.25 mg/kg/dose) or placebo (1:1) was administered twice daily for 6 consecutive days. Two days after treatment initiation with prednisolone or placebo, 5 mg imiquimod (IMQ) once daily for two following days was applied under occlusion on the tape-stripped skin of the back for 48 h in healthy volunteers. Non-invasive (imaging and biophysical) and invasive (skin punch biopsies and blister induction) assessments were performed, as well as IMQ ex vivo stimulation of whole blood. Prednisolone reduced blood perfusion and skin erythema following 48 h of IMQ application (95% CI [−26.4%, −4.3%], p = 0.0111 and 95% CI [−7.96, −2.13], p = 0.0016). Oral prednisolone suppressed the IMQ-elevated total cell count (95% CI [−79.7%, −16.3%], p = 0.0165), NK and dendritic cells (95% CI [−68.7%, −5.2%], p = 0.0333, 95% CI [−76.9%, −13.9%], p = 0.0184), and classical monocytes (95% CI [−76.7%, −26.6%], p = 0.0043) in blister fluid. Notably, TNF, IL-6, IL-8, and Mx-A responses in blister exudate were also reduced by prednisolone compared to placebo. Oral prednisolone suppresses IMQ-induced skin inflammation, which underlines the value of this cutaneous challenge model in clinical pharmacology studies of novel anti-inflammatory compounds. In these studies, prednisolone can be used as a benchmark

Toward Precision Top Quark Measurements in e+e−e^+e^− Collisions at Linear Colliders

Linear lepton colliders offer an excellent environment for precision measurements of the top quark. An overview is given of the current prospects on the measurement of the top quark mass, rare top quark decays and top quark couplings at the International Linear Collider (ILC) and the Compact Linear Collider (CLIC)

Detailed studies of hadronic showers and comparison to GEANT4 simulations with data from highly granular calorimeters

The highly granular calorimeter prototypes of the CALICE collaboration have provided large data samples with precise three-dimensional information on hadronic showers with steel and tungsten absorbers and silicon, scintillator and gas detector readout. From these data sets, detailed measurements of the spatial structure, including longitudinal and lateral shower profiles and of the shower substructure and time structure are extracted. Recent analyses have extended these studies to different particle species in calorimeters with scintillator readout and steel and tungsten absorbers, to energies below 10 GeV in a silicon tungsten calorimeter and have provided first studies of the shower substructure with gaseous readout and unprecedented granularity of $1\times1$~cm$^{2}$ over a full cubic meter. These results are confronted with Geant4 simulations with different hadronic physics models. They present new challenges to the simulation codes and provide the possibility to validate and improve the simulation of hadronic interactions in high-energy physics detectors